This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Cancer				
Endometrial cancer	Protein phosphatase methyltransferase 1 (PPME1)	<i>In vitro</i> , primary tumor and mouse studies suggest inhibiting PPME1 could help treat endometrial cancer. In multiple human endometrial cancer cell lines or primary endometrial tumors, PPME1 levels were higher than those in a human endocervical cell line or surrounding normal tissue. In the cancer cell lines, PPME1 overexpression increased proliferation and PPME1-targeting shRNA or siRNA decreased proliferation compared with normal PPME1 expression or scrambled shRNA or siRNA. In mice, human endometrial cancer cells modified to overexpress PPME1 produced larger tumors than the unmodified cell line. Ongoing work by the Oncoveda unit of Medical Diagnostics Laboratories LLC includes testing PPME1 inhibition in mouse models of endometrial cancer.	Unpatented; available for licensing or partnering	Wandzioch, E. <i>et al. Cancer Res.</i> ; published online June 13, 2014; doi:10.1158/0008-5472.CAN-13-3130 Contact: Lyndi M. Rice, Oncoveda, Hamilton, N.J. e-mail: lrice@oncoveda.com
SciBX 7(28); doi:10.1038/scibx.2014.824 Published online July 24, 2014				